Technical420 Site Search

TORONTO, Aug. 1, 2023 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has made its first delivery to the United States, and has completed the US FDA drug API…

Barrie, Ontario–(Newsfile Corp. – December 22, 2022) – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) and VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (“VIVO”) today announced that MediPharm and VIVO have entered into a definitive arrangement agreement (the “Arrangement Agreement”) whereby MediPharm has agreed to…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug…

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt. “MediPharm continues on its plan and path to profitability, and…

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on the significant strategic profitability improvement initiatives underway at the Company. “Although the cannabis industry has seen a pull back in the capital markets, I remain extremely positive…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a medical cannabis export to Barbados in conjunction with strategic partner Avicanna (TSX: AVCN). “Our GMP platform make us the go-to partner for companies looking to access…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the expansion of its unique cannabinol (“CBN”) product line. “Once again MediPharm Labs continues to innovate and commercialize unique cannabinoids. Our exciting new CBN:CBD is a unique formulation that allows…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids today announced its financial results for the three and nine months ended September 30, 2021, a period of transition in establishing itself as an international pharmaceutical company specializing in cannabis. Q3 2021 Key Highlights…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company that specializes in cannabis, is pleased to announce that it has received approval to ship medical cannabis oil to Brazil. This approval, issued by both ANVISA and Health Canada, allows initial shipments to…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021, a period of ongoing progress in…